首页> 外文期刊>Italian Journal of Medicine >Antithrombotic drugs with adjuvant action against COVID-19
【24h】

Antithrombotic drugs with adjuvant action against COVID-19

机译:对Covid-19的辅助作用的抗血栓形成药物

获取原文
           

摘要

Waiting for the vaccine and/or the best antiviral treatment for coronavirus infection disease 2019 (COVID-19), after its outbreak in China at the beginning of 2020 and its viral diffusion around the world in the following weeks, several drugs have been suggested for their potential adjuvant support against infection. Several drugs have been suggested to have a potential ancillary antiviral role. Circulating proteins, in particular proteases and peptidases regulated by drug functions, may interact with well-known drugs like anticoagulants, antihypertensives, antiserotoninergics, and so also with viral proteases. We here report a brief list of these drugs (i.e., heparinoids, flavonoids, antiplatelets, anticoagulants) that may interact with COVID-19.
机译:等待疫苗和/或最佳抗病毒治疗冠状病毒感染疾病2019(Covid-19),在2020年初爆发后,在接下来的几周内世界各地的病毒扩散,已经提出了几种药物他们潜在的佐剂对感染的支持。已经提出了几种药物具有潜在的辅助抗病毒作用。循环蛋白质,特别是通过药物功能调节的蛋白酶和肽酶,可以与抗凝血剂,抗高血压,抗菌阳胆管剂等众所周知的药物相互作用,也可以与病毒蛋白酶等。我们在这里举报了这些药物的简要列表(即肝素类化合物,黄酮类化合物,抗涂膜,抗凝血剂),其可以与Covid-19相互作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号